Work

The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma

Year: 2025

Type: article

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.mct-24-0972

Authors: Racha Hosni, Niklas Klümper, Christine Sanders, Sana Hosni, Vittorio Branchi, Alexander Semaan, Abdullah Alajati, Natalie Pelusi, Susanna S. Ng, Damian J. Ralser, Saif-Eldin Abedellatif, Hanno Matthaei, Jörg Kalff, Jasmitha Boovadira Poonacha, Veronika Lukacs-Kornek, Glen Kristiansen, Maria A. Gonzalez-Carmona, Michael Hölzel, Marieta I. Toma

Institutions: University Hospital Bonn, The University of Texas MD Anderson Cancer Center, University of Bonn

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Deutsche Forschungsgemeinschaft

Award: EXC 2151: ImmunoSensation2 the immune sensory system

OpenAlex ID: W4411285967

FWCI: 5.192

Cites: 49

Cited by: 6

Related to: 10